{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:39:41Z","timestamp":1792795181596,"version":"4.5.0"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cerebellum"],"DOI":"10.1007\/s12311-026-02086-z","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:39:05Z","timestamp":1790141945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroprotection Across Cerebellar and Nigrostriatal Degeneration: Translational Insights from Parkinson\u2019s Disease to Spinocerebellar Ataxia Type 2"],"prefix":"10.1007","volume":"25","author":[{"given":"Luis Arturo","family":"Fonseca-Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Pav\u00f3n","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor Diogenes Amaral","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Lima","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Vel\u00e1zquez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanier","family":"N\u00fa\u00f1ez-Figueredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2086_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/bs.irn.2019.10.019","volume":"149","author":"M Synofzik","year":"2019","unstructured":"Synofzik M. Parkinsonism in neurodegenerative diseases predominantly presenting with ataxia. Int Rev Neurobiol. 2019;149:277\u201398. https:\/\/doi.org\/10.1016\/bs.irn.2019.10.019.","journal-title":"Int Rev Neurobiol"},{"key":"2086_CR2","doi-asserted-by":"publisher","first-page":"120020","DOI":"10.1016\/j.jns.2021.120020","volume":"433","author":"G Franco","year":"2022","unstructured":"Franco G, Lazzeri G, Di Fonzo A. Parkinsonism and ataxia. J Neurol Sci. 2022;433:120020. https:\/\/doi.org\/10.1016\/j.jns.2021.120020.","journal-title":"J Neurol Sci"},{"key":"2086_CR3","doi-asserted-by":"publisher","first-page":"125273","DOI":"10.1155\/2015\/125273","volume":"2015","author":"H Park","year":"2015","unstructured":"Park H, Kim HJ, Jeon BS. Parkinsonism in spinocerebellar ataxia. Biomed Res Int. 2015;2015:125273. https:\/\/doi.org\/10.1155\/2015\/125273.","journal-title":"Biomed Res Int"},{"key":"2086_CR4","doi-asserted-by":"publisher","first-page":"1661707","DOI":"10.3389\/fneur.2025.1661707","volume":"16","author":"S Wei","year":"2025","unstructured":"Wei S, Zhao Z, Li N, Guo X, Chen J, Hu J. Spinocerebellar ataxias masquerading as movement disorders: clinical and genetic characterization. Front Neurol. 2025;16:1661707. https:\/\/doi.org\/10.3389\/fneur.2025.1661707.","journal-title":"Front Neurol"},{"key":"2086_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3389\/fneur.2017.00472","volume":"8","author":"LC Velazquez-Perez","year":"2017","unstructured":"Velazquez-Perez LC, Rodriguez-Labrada R, Fernandez-Ruiz J. Spinocerebellar Ataxia Type 2: Clinicogenetic Aspects, Mechanistic Insights, and Management Approaches. Front Neurol. 2017;8:472. https:\/\/doi.org\/10.3389\/fneur.2017.00472.","journal-title":"Front Neurol"},{"issue":"5","key":"2086_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner CM, Ostrem JL. Parkinson\u2019s Disease. N Engl J Med. 2024;391(5):442\u201352. https:\/\/doi.org\/10.1056\/NEJMra2401857.","journal-title":"N Engl J Med"},{"issue":"1","key":"2086_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):73. https:\/\/doi.org\/10.1038\/s41392-023-01353-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"10423","key":"2086_CR8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of Parkinson\u2019s disease. Lancet. 2024;403(10423):293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2.","journal-title":"Lancet"},{"issue":"6","key":"2086_CR9","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00702-024-02788-w","volume":"131","author":"H Mochizuki","year":"2024","unstructured":"Mochizuki H. Pathological mechanisms and treatment of sporadic Parkinson\u2019s disease: past, present, and future. J Neural Transm (Vienna). 2024;131(6):597\u2013607. https:\/\/doi.org\/10.1007\/s00702-024-02788-w.","journal-title":"J Neural Transm (Vienna)"},{"issue":"Pt 6","key":"2086_CR10","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/brain\/awl081","volume":"129","author":"AM Duenas","year":"2006","unstructured":"Duenas AM, Goold R, Giunti P. Molecular pathogenesis of spinocerebellar ataxias. Brain. 2006;129(Pt 6):1357\u201370. https:\/\/doi.org\/10.1093\/brain\/awl081.","journal-title":"Brain"},{"key":"2086_CR11","doi-asserted-by":"publisher","first-page":"1422442","DOI":"10.3389\/fnins.2024.1422442","volume":"18","author":"ZT Cui","year":"2024","unstructured":"Cui ZT, Mao ZT, Yang R, et al. Spinocerebellar ataxias: from pathogenesis to recent therapeutic advances. Front Neurosci. 2024;18:1422442. https:\/\/doi.org\/10.3389\/fnins.2024.1422442.","journal-title":"Front Neurosci"},{"issue":"11 Pt B","key":"2086_CR12","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.bbamcr.2018.05.009","volume":"1865","author":"C Hisatsune","year":"2018","unstructured":"Hisatsune C, Hamada K, Mikoshiba K. Ca(2+) signaling and spinocerebellar ataxia. Biochim Biophys Acta Mol Cell Res. 2018;1865(11 Pt B):1733\u201344. https:\/\/doi.org\/10.1016\/j.bbamcr.2018.05.009.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"2086_CR13","doi-asserted-by":"publisher","first-page":"9875639","DOI":"10.1155\/2021\/9875639","volume":"2021","author":"AG Dennis","year":"2021","unstructured":"Dennis AG, Almaguer-Mederos LE, Raul RA, et al. Redox Imbalance Associates with Clinical Worsening in Spinocerebellar Ataxia Type 2. Oxid Med Cell Longev. 2021;2021:9875639. https:\/\/doi.org\/10.1155\/2021\/9875639.","journal-title":"Oxid Med Cell Longev"},{"key":"2086_CR14","doi-asserted-by":"publisher","unstructured":"Mohd Hisam NS, Wong KH. Oxidative stress in spinocerebellar ataxia type 3 and its attenuation by herbal remedies in traditional chinese medicine: a systematic review. Antioxid (Basel). 2024;13(3). https:\/\/doi.org\/10.3390\/antiox13030375.","DOI":"10.3390\/antiox13030375"},{"issue":"4","key":"2086_CR15","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1007\/s13311-020-00941-3","volume":"17","author":"SL Perlman","year":"2020","unstructured":"Perlman SL. Update on the Treatment of Ataxia: Medication and Emerging Therapies. Neurotherapeutics. 2020;17(4):1660\u20134. https:\/\/doi.org\/10.1007\/s13311-020-00941-3.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2086_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14737175.2022.2029703","volume":"22","author":"SD Ghanekar","year":"2022","unstructured":"Ghanekar SD, Kuo SH, Staffetti JS, Zesiewicz TA. Current and emerging treatment modalities for spinocerebellar ataxias. Expert Rev Neurother. 2022;22(2):101\u201314. https:\/\/doi.org\/10.1080\/14737175.2022.2029703.","journal-title":"Expert Rev Neurother"},{"issue":"Suppl 3","key":"2086_CR17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1002\/mdc3.70190","volume":"12 Suppl 3","author":"K Eguchi","year":"2025","unstructured":"Eguchi K, Yaguchi H, Yabe I. Ataxia. Mov Disord Clin Pract. 2025;12 Suppl 3(Suppl 3):S31\u20135. https:\/\/doi.org\/10.1002\/mdc3.70190.","journal-title":"Mov Disord Clin Pract"},{"key":"2086_CR18","doi-asserted-by":"publisher","unstructured":"Sequeira L, Benfeito S, Fernandes C, et al. Drug Development for Alzheimer\u2019s and Parkinson\u2019s Disease. Where Do We Go Now? Pharmaceutics. 2024;16(6). https:\/\/doi.org\/10.3390\/pharmaceutics16060708.","DOI":"10.3390\/pharmaceutics16060708"},{"issue":"Suppl 1","key":"2086_CR19","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/S1353-8020(13)70032-4","volume":"20","author":"MB Youdim","year":"2014","unstructured":"Youdim MB, Kupershmidt L, Amit T, Weinreb O Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20(Suppl 1):S132\u20136. https:\/\/doi.org\/10.1016\/S1353-8020(13)70032-4.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"2086_CR20","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, Oz G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14(10):590\u2013605. https:\/\/doi.org\/10.1038\/s41582-018-0051-6.","journal-title":"Nat Rev Neurol"},{"issue":"12","key":"2086_CR21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41582-025-01136-0","volume":"21","author":"T Wirth","year":"2025","unstructured":"Wirth T, Faber J, Depienne C, et al. Progress and challenges in sporadic late-onset cerebellar ataxias. Nat Rev Neurol. 2025;21(12):687\u2013705. https:\/\/doi.org\/10.1038\/s41582-025-01136-0.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2086_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12035-020-02116-9","volume":"58","author":"MS Uddin","year":"2021","unstructured":"Uddin MS, Al Mamun A, Kabir MT, Ashraf GM, Bin-Jumah MN, Abdel-Daim MM. Multi-Target Drug Candidates for Multifactorial Alzheimer\u2019s Disease: AChE and NMDAR as Molecular Targets. Mol Neurobiol. 2021;58(1):281\u2013303. https:\/\/doi.org\/10.1007\/s12035-020-02116-9.","journal-title":"Mol Neurobiol"},{"issue":"3","key":"2086_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1586\/ecp.11.13","volume":"4","author":"CJ Van der Schyf","year":"2011","unstructured":"Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases. Expert Rev Clin Pharmacol. 2011;4(3):293\u20138. https:\/\/doi.org\/10.1586\/ecp.11.13.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"2086_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.tips.2004.11.007","volume":"26","author":"MB Youdim","year":"2005","unstructured":"Youdim MB, Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci. 2005;26(1):27\u201335. https:\/\/doi.org\/10.1016\/j.tips.2004.11.007.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"2086_CR25","doi-asserted-by":"publisher","first-page":"e0011","DOI":"10.5041\/RMMJ.10011","volume":"1","author":"MB Youdim","year":"2010","unstructured":"Youdim MB. Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson\u2019s and Alzheimer\u2019s disorders? Rambam Maimonides Med J. 2010;1(2):e0011. https:\/\/doi.org\/10.5041\/RMMJ.10011.","journal-title":"Rambam Maimonides Med J"},{"issue":"10423","key":"2086_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","volume":"403","author":"T Foltynie","year":"2024","unstructured":"Foltynie T, Bruno V, Fox S, Kuhn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson\u2019s disease. Lancet. 2024;403(10423):305\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(23)01429-0.","journal-title":"Lancet"},{"key":"2086_CR27","doi-asserted-by":"publisher","first-page":"102357","DOI":"10.1016\/j.arr.2024.102357","volume":"99","author":"DG Gadhave","year":"2024","unstructured":"Gadhave DG, Sugandhi VV, Jha SK, et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev. 2024;99:102357. https:\/\/doi.org\/10.1016\/j.arr.2024.102357.","journal-title":"Ageing Res Rev"},{"issue":"3","key":"2086_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1582-4934.2010.01010.x","volume":"14","author":"KA Jellinger","year":"2010","unstructured":"Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14(3):457\u201387. https:\/\/doi.org\/10.1111\/j.1582-4934.2010.01010.x.","journal-title":"J Cell Mol Med"},{"key":"2086_CR29","doi-asserted-by":"publisher","unstructured":"Aijaz M, Ahmad S. Parkinson\u2019s disease: molecular mechanisms, metabolic interactions, biomarkers, and emerging therapeutic targets. Neurol Clin Neurosci. https:\/\/doi.org\/10.1002\/ncn3.70131.","DOI":"10.1002\/ncn3.70131"},{"issue":"6","key":"2086_CR30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41419-024-06812-5","volume":"15","author":"RG Costa","year":"2024","unstructured":"Costa RG, Conceicao A, Matos CA, Nobrega C. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease. Cell Death Dis. 2024;15(6):415. https:\/\/doi.org\/10.1038\/s41419-024-06812-5.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2086_CR31","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s12311-023-01625-2","volume":"23","author":"W Ilg","year":"2024","unstructured":"Ilg W, Milne S, Schmitz-Hubsch T, et al. Quantitative Gait and Balance Outcomes for Ataxia Trials: Consensus Recommendations by the Ataxia Global Initiative Working Group on Digital-Motor Biomarkers. Cerebellum. 2024;23(4):1566\u201392. https:\/\/doi.org\/10.1007\/s12311-023-01625-2.","journal-title":"Cerebellum"},{"issue":"7","key":"2086_CR32","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/mds.20090","volume":"19","author":"J Infante","year":"2004","unstructured":"Infante J, Berciano J, Volpini V, et al. Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease. Mov Disord. 2004;19(7):848\u201352. https:\/\/doi.org\/10.1002\/mds.20090.","journal-title":"Mov Disord"},{"issue":"4","key":"2086_CR33","doi-asserted-by":"publisher","first-page":"e70445","DOI":"10.1111\/jnc.70445","volume":"170","author":"S Obika","year":"2026","unstructured":"Obika S, Blesa J. Antisense Oligonucleotides in Parkinson\u2019s Disease: Challenges, Opportunities, and the Promise of Low-Intensity Focused Ultrasound for Brain Delivery. J Neurochem. 2026;170(4):e70445. https:\/\/doi.org\/10.1111\/jnc.70445.","journal-title":"J Neurochem"},{"issue":"s2","key":"2086_CR34","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.3233\/JPD-230354","volume":"14","author":"P Mahlknecht","year":"2024","unstructured":"Mahlknecht P, Poewe W. Pharmacotherapy for Disease Modification in Early Parkinson\u2019s Disease: How Early Should We Be? J Parkinsons Dis. 2024;14(s2):S407\u201321. https:\/\/doi.org\/10.3233\/JPD-230354.","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"2086_CR35","doi-asserted-by":"publisher","first-page":"e209749","DOI":"10.1212\/WNL.0000000000209749","volume":"103","author":"G Coarelli","year":"2024","unstructured":"Coarelli G, Dubec-Fleury C, Petit E, et al. Longitudinal Changes of Clinical, Imaging, and Fluid Biomarkers in Preataxic and Early Ataxic Spinocerebellar Ataxia Type 2 and 7 Carriers. Neurology. 2024;103(5):e209749. https:\/\/doi.org\/10.1212\/WNL.0000000000209749.","journal-title":"Neurology"},{"issue":"3","key":"2086_CR36","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s12311-023-01543-3","volume":"23","author":"M Grobe-Einsler","year":"2024","unstructured":"Grobe-Einsler M, Amin AT, Faber J, Volkel H, Synofzik M, Klockgether T. Scale for the Assessment and Rating of Ataxia (SARA): Development of a Training Tool and Certification Program. Cerebellum. 2024;23(3):877\u201380. https:\/\/doi.org\/10.1007\/s12311-023-01543-3.","journal-title":"Cerebellum"},{"key":"2086_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinph.2021.12.005","volume":"135","author":"L Velazquez-Perez","year":"2022","unstructured":"Velazquez-Perez L, Rodriguez-Labrada R, Gonzalez-Garces Y, Vazquez-Mojena Y, Perez-Rodriguez R, Ziemann U. Neurophysiological features in spinocerebellar ataxia type 2: Prospects for novel biomarkers. Clin Neurophysiol. 2022;135:1\u201312. https:\/\/doi.org\/10.1016\/j.clinph.2021.12.005.","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"2086_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/mdc3.12590","volume":"5","author":"N Pavese","year":"2018","unstructured":"Pavese N, Tai YF. Nigrosome Imaging and Neuromelanin Sensitive MRI in Diagnostic Evaluation of Parkinsonism. Mov Disord Clin Pract. 2018;5(2):131\u201340. https:\/\/doi.org\/10.1002\/mdc3.12590.","journal-title":"Mov Disord Clin Pract"},{"key":"2086_CR39","doi-asserted-by":"publisher","unstructured":"Szylak E, Czarnowska A, Kulczynska-Przybik A, et al. Neurofilament light chain as a biomarker in neurology. Eur Neurol. 2026;1\u201312. https:\/\/doi.org\/10.1159\/000552933.","DOI":"10.1159\/000552933"},{"issue":"1","key":"2086_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11306-016-1143-1","volume":"13","author":"V Kantae","year":"2017","unstructured":"Kantae V, Krekels EHJ, Esdonk MJV, et al. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics. 2017;13(1):9. https:\/\/doi.org\/10.1007\/s11306-016-1143-1.","journal-title":"Metabolomics"},{"key":"2086_CR41","doi-asserted-by":"publisher","unstructured":"Ayupova AI, Solovyeva VV, Issa SS, Fayoud HJ, Rizvanov AA. Surrogate biomarkers in gene therapy for orphan diseases: validation, application, and regulatory aspects. Int J Mol Sci. 2025;26(20). https:\/\/doi.org\/10.3390\/ijms262010107.","DOI":"10.3390\/ijms262010107"},{"issue":"14","key":"2086_CR42","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1097\/00001756-200310060-00008","volume":"14","author":"C Brenneis","year":"2003","unstructured":"Brenneis C, Bosch SM, Schocke M, Wenning GK, Poewe W. Atrophy pattern in SCA2 determined by voxel-based morphometry. NeuroReport. 2003;14(14):1799\u2013802. https:\/\/doi.org\/10.1097\/00001756-200310060-00008.","journal-title":"NeuroReport"},{"issue":"4","key":"2086_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00415-025-13051-x","volume":"272","author":"W Kou","year":"2025","unstructured":"Kou W, Li S, Yan R, Zhang J, Wan Z, Feng T. Cerebrospinal fluid and blood neurofilament light chain in Parkinson\u2019s disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis. J Neurol. 2025;272(4):311. https:\/\/doi.org\/10.1007\/s00415-025-13051-x.","journal-title":"J Neurol"},{"issue":"24","key":"2086_CR44","doi-asserted-by":"publisher","first-page":"e2404","DOI":"10.1212\/WNL.0000000000012945","volume":"97","author":"L Yang","year":"2021","unstructured":"Yang L, Shao YR, Li XY, Ma Y, Dong Y, Wu ZY. Association of the Level of Neurofilament Light With Disease Severity in Patients With Spinocerebellar Ataxia Type 2. Neurology. 2021;97(24):e2404\u201313. https:\/\/doi.org\/10.1212\/WNL.0000000000012945.","journal-title":"Neurology"},{"issue":"1","key":"2086_CR45","doi-asserted-by":"publisher","first-page":"42559","DOI":"10.1038\/s41598-025-29070-7","volume":"15","author":"LE Almaguer-Mederos","year":"2025","unstructured":"Almaguer-Mederos LE, Key J, Sen NE, et al. Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2. Sci Rep. 2025;15(1):42559. https:\/\/doi.org\/10.1038\/s41598-025-29070-7.","journal-title":"Sci Rep"},{"key":"2086_CR46","doi-asserted-by":"publisher","unstructured":"Zhang S, Wang T, Peng Y, et al. Parkinson\u2019s disease: pathogenesis and therapeutic strategies. Mol Biomed. 2026;7(1). https:\/\/doi.org\/10.1186\/s43556-026-00445-0.","DOI":"10.1186\/s43556-026-00445-0"},{"issue":"4","key":"2086_CR47","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.jbc.2021.101191","volume":"297","author":"M Gandelman","year":"2021","unstructured":"Gandelman M, Dansithong W, Kales SC, et al. The AKT modulator A-443654 reduces alpha-synuclein expression and normalizes ER stress and autophagy. J Biol Chem. 2021;297(4):101191. https:\/\/doi.org\/10.1016\/j.jbc.2021.101191.","journal-title":"J Biol Chem"},{"issue":"1","key":"2086_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/archneur.61.1.35","volume":"61","author":"CS Lu","year":"2004","unstructured":"Lu CS, Wu Chou YH, Kuo PC, Chang HC, Weng YH. The parkinsonian phenotype of spinocerebellar ataxia type 2. Arch Neurol. 2004;61(1):35\u20138. https:\/\/doi.org\/10.1001\/archneur.61.1.35.","journal-title":"Arch Neurol"},{"issue":"1","key":"2086_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ejhg.2011.154","volume":"20","author":"JM Laffita-Mesa","year":"2012","unstructured":"Laffita-Mesa JM, Velazquez-Perez LC, Santos Falcon N, et al. Unexpanded and intermediate CAG polymorphisms at the SCA2 locus (ATXN2) in the Cuban population: evidence about the origin of expanded SCA2 alleles. Eur J Hum Genet. 2012;20(1):41\u20139. https:\/\/doi.org\/10.1038\/ejhg.2011.154.","journal-title":"Eur J Hum Genet"},{"issue":"21","key":"2086_CR50","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1212\/01.wnl.0000269323.21969.db","volume":"69","author":"P Charles","year":"2007","unstructured":"Charles P, Camuzat A, Benammar N, et al. Are interrupted SCA2 CAG repeat expansions responsible for parkinsonism? Neurology. 2007;69(21):1970\u20135. https:\/\/doi.org\/10.1212\/01.wnl.0000269323.21969.db.","journal-title":"Neurology"},{"issue":"6","key":"2086_CR51","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ana.10055","volume":"50","author":"DE Shan","year":"2001","unstructured":"Shan DE, Soong BW, Sun CM, Lee SJ, Liao KK, Liu RS. Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism. Ann Neurol. 2001;50(6):812\u20135. https:\/\/doi.org\/10.1002\/ana.10055.","journal-title":"Ann Neurol"},{"key":"2086_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.parkreldis.2017.04.003","volume":"40","author":"YE Kim","year":"2017","unstructured":"Kim YE, Jeon B, Farrer MJ, et al. SCA2 family presenting as typical Parkinson\u2019s disease: 34 year follow up. Parkinsonism Relat Disord. 2017;40:69\u201372. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.04.003.","journal-title":"Parkinsonism Relat Disord"},{"issue":"16","key":"2086_CR53","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/hmg\/ddr227","volume":"20","author":"OA Ross","year":"2011","unstructured":"Ross OA, Rutherford NJ, Baker M, et al. Ataxin-2 repeat-length variation and neurodegeneration. Hum Mol Genet. 2011;20(16):3207\u201312. https:\/\/doi.org\/10.1093\/hmg\/ddr227.","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2086_CR54","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.4103\/1673-5374.338996","volume":"17","author":"JM Laffita-Mesa","year":"2022","unstructured":"Laffita-Mesa JM, Paucar M, Svenningsson P. Are ATXN2 variants modifying our understanding about neural pathogenesis, phenotypes, and diagnostic? Neural Regen Res. 2022;17(11):2445\u20137. https:\/\/doi.org\/10.4103\/1673-5374.338996.","journal-title":"Neural Regen Res"},{"issue":"8","key":"2086_CR55","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1093\/brain\/awac167","volume":"145","author":"JD Glass","year":"2022","unstructured":"Glass JD, Dewan R, Ding J, et al. ATXN2 intermediate expansions in amyotrophic lateral sclerosis. Brain. 2022;145(8):2671\u20136. https:\/\/doi.org\/10.1093\/brain\/awac167.","journal-title":"Brain"},{"issue":"1","key":"2086_CR56","doi-asserted-by":"publisher","first-page":"e70035","DOI":"10.1111\/ene.70035","volume":"32","author":"L Chougar","year":"2025","unstructured":"Chougar L, Coarelli G, Lejeune FX, et al. Substantia nigra degeneration in spinocerebellar ataxia 2 and 7 using neuromelanin-sensitive imaging. Eur J Neurol. 2025;32(1):e70035. https:\/\/doi.org\/10.1111\/ene.70035.","journal-title":"Eur J Neurol"},{"issue":"3","key":"2086_CR57","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s004010050989","volume":"97","author":"R Estrada","year":"1999","unstructured":"Estrada R, Galarraga J, Orozco G, Nodarse A, Auburger G. Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies. Acta Neuropathol. 1999;97(3):306\u201310. https:\/\/doi.org\/10.1007\/s004010050989.","journal-title":"Acta Neuropathol"},{"key":"2086_CR58","doi-asserted-by":"publisher","unstructured":"Takao M, Aoyama M, Ishikawa K, et al. Spinocerebellar ataxia type 2 is associated with Parkinsonism and Lewy body pathology. BMJ Case Rep. 2011;2011. https:\/\/doi.org\/10.1136\/bcr.01.2011.3685.","DOI":"10.1136\/bcr.01.2011.3685"},{"issue":"3","key":"2086_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S1474-4422(22)00028-X","volume":"21","author":"L Velazquez-Perez","year":"2022","unstructured":"Velazquez-Perez L, Rodriguez-Labrada R. Riluzole and spinocerebellar ataxia type 2: the ATRIL trial. Lancet Neurol. 2022;21(3):204\u20135. https:\/\/doi.org\/10.1016\/S1474-4422(22)00028-X.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2086_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12035-012-8348-8","volume":"47","author":"JJ Magana","year":"2013","unstructured":"Magana JJ, Velazquez-Perez L, Cisneros B. Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives. Mol Neurobiol. 2013;47(1):90\u2013104. https:\/\/doi.org\/10.1007\/s12035-012-8348-8.","journal-title":"Mol Neurobiol"},{"issue":"12","key":"2086_CR61","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41582-018-0102-z","volume":"14","author":"T Ashizawa","year":"2018","unstructured":"Ashizawa T, Oz G, Paulson HL. Author Correction: Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol. 2018;14(12):749. https:\/\/doi.org\/10.1038\/s41582-018-0102-z.","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"2086_CR62","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/kjm2.12106","volume":"35","author":"CS Chuang","year":"2019","unstructured":"Chuang CS, Chang JC, Soong BW, et al. Treadmill training increases the motor activity and neuron survival of the cerebellum in a mouse model of spinocerebellar ataxia type 1. Kaohsiung J Med Sci. 2019;35(11):679\u201385. https:\/\/doi.org\/10.1002\/kjm2.12106.","journal-title":"Kaohsiung J Med Sci"},{"issue":"22","key":"2086_CR63","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1212\/WNL.0b013e3181c33adf","volume":"73","author":"W Ilg","year":"2009","unstructured":"Ilg W, Synofzik M, Brotz D, Burkard S, Giese MA, Schols L. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology. 2009;73(22):1823\u201330. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c33adf.","journal-title":"Neurology"},{"issue":"13","key":"2086_CR64","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/mds.23222","volume":"25","author":"W Ilg","year":"2010","unstructured":"Ilg W, Brotz D, Burkard S, Giese MA, Schols L, Synofzik M. Long-term effects of coordinative training in degenerative cerebellar disease. Mov Disord. 2010;25(13):2239\u201346. https:\/\/doi.org\/10.1002\/mds.23222.","journal-title":"Mov Disord"},{"issue":"9","key":"2086_CR65","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/mds.27437","volume":"33","author":"JC Rodriguez-Diaz","year":"2018","unstructured":"Rodriguez-Diaz JC, Velazquez-Perez L, Rodriguez Labrada R, et al. Neurorehabilitation therapy in spinocerebellar ataxia type 2: A 24-week, rater-blinded, randomized, controlled trial. Mov Disord. 2018;33(9):1481\u20137. https:\/\/doi.org\/10.1002\/mds.27437.","journal-title":"Mov Disord"},{"key":"2086_CR66","doi-asserted-by":"publisher","first-page":"583507","DOI":"10.1155\/2014\/583507","volume":"2014","author":"M Synofzik","year":"2014","unstructured":"Synofzik M, Ilg W. Motor training in degenerative spinocerebellar disease: ataxia-specific improvements by intensive physiotherapy and exergames. Biomed Res Int. 2014;2014:583507. https:\/\/doi.org\/10.1155\/2014\/583507.","journal-title":"Biomed Res Int"},{"issue":"20","key":"2086_CR67","doi-asserted-by":"publisher","first-page":"20611","DOI":"10.18632\/aging.103946","volume":"12","author":"P Song","year":"2020","unstructured":"Song P, Li S, Wang S, Wei H, Lin H, Wang Y. Repetitive transcranial magnetic stimulation of the cerebellum improves ataxia and cerebello-fronto plasticity in multiple system atrophy: a randomized, double-blind, sham-controlled and TMS-EEG study. Aging. 2020;12(20):20611\u201322. https:\/\/doi.org\/10.18632\/aging.103946.","journal-title":"Aging"},{"issue":"3","key":"2086_CR68","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12311-019-1006-1","volume":"18","author":"K Tercero-Perez","year":"2019","unstructured":"Tercero-Perez K, Cortes H, Torres-Ramos Y, et al. Effects of Physical Rehabilitation in Patients with Spinocerebellar Ataxia Type 7. Cerebellum. 2019;18(3):397\u2013405. https:\/\/doi.org\/10.1007\/s12311-019-1006-1.","journal-title":"Cerebellum"},{"key":"2086_CR69","doi-asserted-by":"publisher","first-page":"1491142","DOI":"10.3389\/fneur.2024.1491142","volume":"15","author":"A Matsugi","year":"2024","unstructured":"Matsugi A, Bando K, Kondo Y, et al. Effects of physiotherapy on degenerative cerebellar ataxia: a systematic review and meta-analysis. Front Neurol. 2024;15:1491142. https:\/\/doi.org\/10.3389\/fneur.2024.1491142.","journal-title":"Front Neurol"},{"key":"2086_CR70","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-444-63356-9.00002-9","volume":"210","author":"E D\u2019Angelo","year":"2014","unstructured":"D\u2019Angelo E. The organization of plasticity in the cerebellar cortex: from synapses to control. Prog Brain Res. 2014;210:31\u201358. https:\/\/doi.org\/10.1016\/B978-0-444-63356-9.00002-9.","journal-title":"Prog Brain Res"},{"key":"2086_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fnsyn.2016.00035","volume":"8","author":"E Hoxha","year":"2016","unstructured":"Hoxha E, Tempia F, Lippiello P, Miniaci MC, Modulation. Plasticity and Pathophysiology of the Parallel Fiber-Purkinje Cell Synapse. Front Synaptic Neurosci. 2016;8:35. https:\/\/doi.org\/10.3389\/fnsyn.2016.00035.","journal-title":"Front Synaptic Neurosci"},{"issue":"8","key":"2086_CR72","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tins.2017.06.004","volume":"40","author":"G Auburger","year":"2017","unstructured":"Auburger G, Sen NE, Meierhofer D, Basak AN, Gitler AD. Efficient Prevention of Neurodegenerative Diseases by Depletion of Starvation Response Factor Ataxin-2. Trends Neurosci. 2017;40(8):507\u201316. https:\/\/doi.org\/10.1016\/j.tins.2017.06.004.","journal-title":"Trends Neurosci"},{"issue":"1","key":"2086_CR73","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12311-016-0762-4","volume":"16","author":"MV Halbach","year":"2017","unstructured":"Halbach MV, Gispert S, Stehning T, Damrath E, Walter M, Auburger G. Atxn2 Knockout and CAG42-Knock-in Cerebellum Shows Similarly Dysregulated Expression in Calcium Homeostasis Pathway. Cerebellum. 2017;16(1):68\u201381. https:\/\/doi.org\/10.1007\/s12311-016-0762-4.","journal-title":"Cerebellum"},{"issue":"9","key":"2086_CR74","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbadis.2016.05.017","volume":"1862","author":"I Lastres-Becker","year":"2016","unstructured":"Lastres-Becker I, Nonis D, Eich F, et al. Mammalian ataxin-2 modulates translation control at the pre-initiation complex via PI3K\/mTOR and is induced by starvation. Biochim Biophys Acta. 2016;1862(9):1558\u201369. https:\/\/doi.org\/10.1016\/j.bbadis.2016.05.017.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"2086_CR75","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.arcmed.2012.09.008","volume":"43","author":"KI Erickson","year":"2012","unstructured":"Erickson KI, Weinstein AM, Lopez OL. Physical activity, brain plasticity, and Alzheimer\u2019s disease. Arch Med Res. 2012;43(8):615\u201321. https:\/\/doi.org\/10.1016\/j.arcmed.2012.09.008.","journal-title":"Arch Med Res"},{"issue":"1","key":"2086_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/sms.12069","volume":"24","author":"T Huang","year":"2014","unstructured":"Huang T, Larsen KT, Ried-Larsen M, Moller NC, Andersen LB. The effects of physical activity and exercise on brain-derived neurotrophic factor in healthy humans: A review. Scand J Med Sci Sports. 2014;24(1):1\u201310. https:\/\/doi.org\/10.1111\/sms.12069.","journal-title":"Scand J Med Sci Sports"},{"key":"2086_CR77","doi-asserted-by":"publisher","first-page":"4716197","DOI":"10.1155\/2017\/4716197","volume":"2017","author":"CP Mackay","year":"2017","unstructured":"Mackay CP, Kuys SS, Brauer SG. The Effect of Aerobic Exercise on Brain-Derived Neurotrophic Factor in People with Neurological Disorders: A Systematic Review and Meta-Analysis. Neural Plast. 2017;2017:4716197. https:\/\/doi.org\/10.1155\/2017\/4716197.","journal-title":"Neural Plast"},{"issue":"4","key":"2086_CR78","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1080\/00222895.2014.983450","volume":"47","author":"AM Singh","year":"2015","unstructured":"Singh AM, Staines WR. The effects of acute aerobic exercise on the primary motor cortex. J Mot Behav. 2015;47(4):328\u201339. https:\/\/doi.org\/10.1080\/00222895.2014.983450.","journal-title":"J Mot Behav"},{"key":"2086_CR79","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2018.02.005","volume":"688","author":"DD Bushart","year":"2019","unstructured":"Bushart DD, Shakkottai VG. Ion channel dysfunction in cerebellar ataxia. Neurosci Lett. 2019;688:41\u20138. https:\/\/doi.org\/10.1016\/j.neulet.2018.02.005.","journal-title":"Neurosci Lett"},{"issue":"10","key":"2086_CR80","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","volume":"14","author":"S Romano","year":"2015","unstructured":"Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14(10):985\u201391. https:\/\/doi.org\/10.1016\/S1474-4422(15)00201-X.","journal-title":"Lancet Neurol"},{"issue":"3","key":"2086_CR81","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1474-4422(21)00457-9","volume":"21","author":"G Coarelli","year":"2022","unstructured":"Coarelli G, Heinzmann A, Ewenczyk C, et al. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2022;21(3):225\u201333. https:\/\/doi.org\/10.1016\/S1474-4422(21)00457-9.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2086_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00415-014-7551-0","volume":"262","author":"F Sacca","year":"2015","unstructured":"Sacca F, Puorro G, Brunetti A, et al. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. J Neurol. 2015;262(1):149\u201353. https:\/\/doi.org\/10.1007\/s00415-014-7551-0.","journal-title":"J Neurol"},{"issue":"22","key":"2086_CR83","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1016\/j.neuron.2023.09.036","volume":"111","author":"LM Thompson","year":"2023","unstructured":"Thompson LM, Orr HT. HD and SCA1: Tales from two 30-year journeys since gene discovery. Neuron. 2023;111(22):3517\u201330. https:\/\/doi.org\/10.1016\/j.neuron.2023.09.036.","journal-title":"Neuron"},{"key":"2086_CR84","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.mito.2017.03.001","volume":"34","author":"N Cornelius","year":"2017","unstructured":"Cornelius N, Wardman JH, Hargreaves IP, et al. Evidence of oxidative stress and mitochondrial dysfunction in spinocerebellar ataxia type 2 (SCA2) patient fibroblasts: Effect of coenzyme Q10 supplementation on these parameters. Mitochondrion. 2017;34:103\u201314. https:\/\/doi.org\/10.1016\/j.mito.2017.03.001.","journal-title":"Mitochondrion"},{"issue":"3","key":"2086_CR85","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1590\/0004-282X20190020","volume":"77","author":"JL Pedroso","year":"2019","unstructured":"Pedroso JL, Vale TC, Braga-Neto P, et al. Acute cerebellar ataxia: differential diagnosis and clinical approach. Arq Neuropsiquiatr. 2019;77(3):184\u201393. https:\/\/doi.org\/10.1590\/0004-282X20190020.","journal-title":"Arq Neuropsiquiatr"},{"issue":"5","key":"2086_CR86","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s40120-025-00793-z","volume":"14","author":"C Gonzalez-Robles","year":"2025","unstructured":"Gonzalez-Robles C, Bandmann O, Schapira AHV. Neuroprotection in Parkinson Disease. Neurol Ther. 2025;14(5):1747\u201367. https:\/\/doi.org\/10.1007\/s40120-025-00793-z.","journal-title":"Neurol Ther"},{"key":"2086_CR87","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnagi.2020.00004","volume":"12","author":"A Iarkov","year":"2020","unstructured":"Iarkov A, Barreto GE, Grizzell JA, Echeverria V. Strategies for the Treatment of Parkinson\u2019s Disease: Beyond Dopamine. Front Aging Neurosci. 2020;12:4. https:\/\/doi.org\/10.3389\/fnagi.2020.00004.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"2086_CR88","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","volume":"30","author":"D Sulzer","year":"2007","unstructured":"Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson\u2019s disease. Trends Neurosci. 2007;30(5):244\u201350. https:\/\/doi.org\/10.1016\/j.tins.2007.03.009.","journal-title":"Trends Neurosci"},{"issue":"5","key":"2086_CR89","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3233\/JPD-240272","volume":"14","author":"K McFarthing","year":"2024","unstructured":"McFarthing K, Buff S, Rafaloff G, et al. Parkinson\u2019s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update. J Parkinsons Dis. 2024;14(5):899\u2013912. https:\/\/doi.org\/10.3233\/JPD-240272.","journal-title":"J Parkinsons Dis"},{"issue":"7Supplement1","key":"2086_CR90","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1212\/WNL.0000000000208468","volume":"104","author":"H Fernandez","year":"2025","unstructured":"Fernandez H, Isaacson S, Hauser R, et al. Efficacy and Safety of Tavapadon, an Orally Administered, Once-daily, Selective D1\/D5 Partial Dopamine Agonist, Adjunctive to Levodopa for Treatment of Parkinson\u2019s Disease with Motor Fluctuations (S37.003). Neurology. 2025;104(7Supplement1):258. https:\/\/doi.org\/10.1212\/WNL.0000000000208468.","journal-title":"Neurology"},{"issue":"648","key":"2086_CR91","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings D, Huntwork-Rodriguez S, Henry AG, et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci Transl Med. 2022;14(648):eabj2658. https:\/\/doi.org\/10.1126\/scitranslmed.abj2658.","journal-title":"Sci Transl Med"},{"issue":"8","key":"2086_CR92","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2025.1687","volume":"82","author":"CRA Silveira","year":"2025","unstructured":"Silveira CRA, Coleman KKL, Borron K, et al. Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2025;82(8):797\u2013807. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1687.","journal-title":"JAMA Neurol"},{"issue":"5","key":"2086_CR93","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00702-019-02115-8","volume":"127","author":"A Salamon","year":"2020","unstructured":"Salamon A, Zadori D, Szpisjak L, Klivenyi P, Vecsei L. Neuroprotection in Parkinson\u2019s disease: facts and hopes. J Neural Transm (Vienna). 2020;127(5):821\u20139. https:\/\/doi.org\/10.1007\/s00702-019-02115-8.","journal-title":"J Neural Transm (Vienna)"},{"key":"2086_CR94","doi-asserted-by":"publisher","unstructured":"Chen K, Wang H, Ilyas I, Mahmood A, Hou L. Microglia and astrocytes dysfunction and key neuroinflammation-based biomarkers in Parkinson\u2019s disease. Brain Sci. 2023;13(4). https:\/\/doi.org\/10.3390\/brainsci13040634.","DOI":"10.3390\/brainsci13040634"},{"issue":"6","key":"2086_CR95","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/mds.25462","volume":"28","author":"B Dehay","year":"2013","unstructured":"Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson\u2019s disease. Mov Disord. 2013;28(6):725\u201332. https:\/\/doi.org\/10.1002\/mds.25462.","journal-title":"Mov Disord"},{"key":"2086_CR96","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuro.2020.11.005","volume":"82","author":"LA Fonseca-Fonseca","year":"2021","unstructured":"Fonseca-Fonseca LA, da Silva VDA, Wong-Guerra M, et al. JM-20 protects against 6-hydroxydopamine-induced neurotoxicity in models of Parkinson\u2019s disease: Mitochondrial protection and antioxidant properties. Neurotoxicology. 2021;82:89\u201398. https:\/\/doi.org\/10.1016\/j.neuro.2020.11.005.","journal-title":"Neurotoxicology"},{"key":"2086_CR97","doi-asserted-by":"publisher","first-page":"115269","DOI":"10.1016\/j.bbr.2024.115269","volume":"476","author":"LA Fonseca-Fonseca","year":"2025","unstructured":"Fonseca-Fonseca LA, Fuentes NP, Sanchez JR, et al. Correlational assessment of the effects of JM-20 in a rat model of parkinsonism. Behav Brain Res. 2025;476:115269. https:\/\/doi.org\/10.1016\/j.bbr.2024.115269.","journal-title":"Behav Brain Res"},{"issue":"7","key":"2086_CR98","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/01616412.2025.2490089","volume":"47","author":"LA Fonseca-Fonseca","year":"2025","unstructured":"Fonseca-Fonseca LA, Tano Portuondo LR, Ramirez-Sanchez J, et al. JM-20 administration to animals with lesion of the nigrostriatal dopamine pathway induced by 6-hydroxydopamine, partially reverses motor damage and oxidative stress. Neurol Res. 2025;47(7):557\u201366. https:\/\/doi.org\/10.1080\/01616412.2025.2490089.","journal-title":"Neurol Res"},{"key":"2086_CR99","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2018.10.008","volume":"690","author":"LA Fonseca-Fonseca","year":"2019","unstructured":"Fonseca-Fonseca LA, Wong-Guerra M, Ramirez-Sanchez J, et al. JM-20, a novel hybrid molecule, protects against rotenone-induced neurotoxicity in experimental model of Parkinson\u2019s disease. Neurosci Lett. 2019;690:29\u201335. https:\/\/doi.org\/10.1016\/j.neulet.2018.10.008.","journal-title":"Neurosci Lett"},{"issue":"6","key":"2086_CR100","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12640-022-00559-7","volume":"40","author":"CC Santos","year":"2022","unstructured":"Santos CC, Cardim-Pires TR, Shvachiy L, et al. JM-20, a Benzodiazepine-Dihydropyridine Hybrid Molecule, Inhibits the Formation of Alpha-Synuclein-Aggregated Species. Neurotox Res. 2022;40(6):2135\u201347. https:\/\/doi.org\/10.1007\/s12640-022-00559-7.","journal-title":"Neurotox Res"},{"issue":"Pt 3","key":"2086_CR101","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/brain\/aws360","volume":"136","author":"T Wu","year":"2013","unstructured":"Wu T, Hallett M. The cerebellum in Parkinson\u2019s disease. Brain. 2013;136(Pt 3):696\u2013709. https:\/\/doi.org\/10.1093\/brain\/aws360.","journal-title":"Brain"},{"key":"2086_CR102","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fneur.2020.00127","volume":"11","author":"L Solstrand Dahlberg","year":"2020","unstructured":"Solstrand Dahlberg L, Lungu O, Doyon J. Cerebellar Contribution to Motor and Non-motor Functions in Parkinson\u2019s Disease: A Meta-Analysis of fMRI Findings. Front Neurol. 2020;11:127. https:\/\/doi.org\/10.3389\/fneur.2020.00127.","journal-title":"Front Neurol"},{"issue":"23","key":"2086_CR103","doi-asserted-by":"publisher","first-page":"e2874","DOI":"10.1212\/WNL.0000000000012036","volume":"96","author":"A Riou","year":"2021","unstructured":"Riou A, Houvenaghel JF, Dondaine T, et al. Functional Role of the Cerebellum in Parkinson Disease: A PET Study. Neurology. 2021;96(23):e2874\u201384. https:\/\/doi.org\/10.1212\/WNL.0000000000012036.","journal-title":"Neurology"},{"issue":"1","key":"2086_CR104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0304-3940(93)90105-t","volume":"150","author":"M Takada","year":"1993","unstructured":"Takada M, Sugimoto T, Hattori T. MPTP neurotoxicity to cerebellar Purkinje cells in mice. Neurosci Lett. 1993;150(1):49\u201352. https:\/\/doi.org\/10.1016\/0304-3940(93)90105-t.","journal-title":"Neurosci Lett"},{"issue":"11","key":"2086_CR105","doi-asserted-by":"publisher","first-page":"111194","DOI":"10.1016\/j.isci.2024.111194","volume":"27","author":"G Liu","year":"2024","unstructured":"Liu G, Yang C, Wang X, Chen X, Cai H, Le W. Cerebellum in neurodegenerative diseases: Advances, challenges, and prospects. iScience. 2024;27(11):111194. https:\/\/doi.org\/10.1016\/j.isci.2024.111194.","journal-title":"iScience"},{"issue":"1","key":"2086_CR106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00401-016-1626-1","volume":"133","author":"SH Kuo","year":"2017","unstructured":"Kuo SH, Lin CY, Wang J, et al. Climbing fiber-Purkinje cell synaptic pathology in tremor and cerebellar degenerative diseases. Acta Neuropathol. 2017;133(1):121\u201338. https:\/\/doi.org\/10.1007\/s00401-016-1626-1.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"2086_CR107","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/mds.22567","volume":"24","author":"ED Louis","year":"2009","unstructured":"Louis ED, Faust PL, Vonsattel JP, et al. Torpedoes in Parkinson\u2019s disease, Alzheimer\u2019s disease, essential tremor, and control brains. Mov Disord. 2009;24(11):1600\u20135. https:\/\/doi.org\/10.1002\/mds.22567.","journal-title":"Mov Disord"},{"issue":"2","key":"2086_CR108","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mds.26479","volume":"31","author":"L Calo","year":"2016","unstructured":"Calo L, Wegrzynowicz M, Santivanez-Perez J, Grazia Spillantini M. Synaptic failure and alpha-synuclein. Mov Disord. 2016;31(2):169\u201377. https:\/\/doi.org\/10.1002\/mds.26479.","journal-title":"Mov Disord"},{"issue":"5","key":"2086_CR109","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/cns.13805","volume":"28","author":"H Fikry","year":"2022","unstructured":"Fikry H, Saleh LA, Abdel Gawad S. Neuroprotective effects of curcumin on the cerebellum in a rotenone-induced Parkinson\u2019s Disease Model. CNS Neurosci Ther. 2022;28(5):732\u201348. https:\/\/doi.org\/10.1111\/cns.13805.","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"2086_CR110","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF01250085","volume":"45","author":"R Adolfsson","year":"1979","unstructured":"Adolfsson R, Gottfries CG, Roos BE, Winblad B. Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J Neural Transm. 1979;45(2):81\u2013105. https:\/\/doi.org\/10.1007\/BF01250085.","journal-title":"J Neural Transm"},{"issue":"4","key":"2086_CR111","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.euroneuro.2018.02.002","volume":"28","author":"E Quansah","year":"2018","unstructured":"Quansah E, Ruiz-Rodado V, Grootveld M, Zetterstrom TSC. Methylphenidate alters monoaminergic and metabolic pathways in the cerebellum of adolescent rats. Eur Neuropsychopharmacol. 2018;28(4):513\u201328. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.02.002.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2086_CR112","doi-asserted-by":"publisher","first-page":"650614","DOI":"10.3389\/fnsys.2021.650614","volume":"15","author":"P Flace","year":"2021","unstructured":"Flace P, Livrea P, Basile GA, et al. The Cerebellar Dopaminergic System. Front Syst Neurosci. 2021;15:650614. https:\/\/doi.org\/10.3389\/fnsys.2021.650614.","journal-title":"Front Syst Neurosci"},{"issue":"9","key":"2086_CR113","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1046\/j.1460-9568.2003.02963.x","volume":"18","author":"MJ Hurley","year":"2003","unstructured":"Hurley MJ, Mash DC, Jenner P. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson\u2019s disease examined by RT-PCR. Eur J Neurosci. 2003;18(9):2668\u201372. https:\/\/doi.org\/10.1046\/j.1460-9568.2003.02963.x.","journal-title":"Eur J Neurosci"},{"issue":"2","key":"2086_CR114","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s00415-009-0092-2","volume":"256","author":"DH Benninger","year":"2009","unstructured":"Benninger DH, Thees S, Kollias SS, Bassetti CL, Waldvogel D. Morphological differences in Parkinson\u2019s disease with and without rest tremor. J Neurol. 2009;256(2):256\u201363. https:\/\/doi.org\/10.1007\/s00415-009-0092-2.","journal-title":"J Neurol"},{"issue":"2","key":"2086_CR115","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1468-1331.2009.02807.x","volume":"17","author":"P Borghammer","year":"2010","unstructured":"Borghammer P, Ostergaard K, Cumming P, et al. A deformation-based morphometry study of patients with early-stage Parkinson\u2019s disease. Eur J Neurol. 2010;17(2):314\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02807.x.","journal-title":"Eur J Neurol"},{"issue":"3","key":"2086_CR116","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.parkreldis.2008.05.002","volume":"15","author":"R Camicioli","year":"2009","unstructured":"Camicioli R, Gee M, Bouchard TP, et al. Voxel-based morphometry reveals extra-nigral atrophy patterns associated with dopamine refractory cognitive and motor impairment in parkinsonism. Parkinsonism Relat Disord. 2009;15(3):187\u201395. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.05.002.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Pt 3","key":"2086_CR117","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/brain\/awv399","volume":"139","author":"C O\u2019Callaghan","year":"2016","unstructured":"O\u2019Callaghan C, Hornberger M, Balsters JH, Halliday GM, Lewis SJ, Shine JM. Cerebellar atrophy in Parkinson\u2019s disease and its implication for network connectivity. Brain. 2016;139(Pt 3):845\u201355. https:\/\/doi.org\/10.1093\/brain\/awv399.","journal-title":"Brain"},{"issue":"6","key":"2086_CR118","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41583-018-0002-7","volume":"19","author":"AC Bostan","year":"2018","unstructured":"Bostan AC, Strick PL. The basal ganglia and the cerebellum: nodes in an integrated network. Nat Rev Neurosci. 2018;19(6):338\u201350. https:\/\/doi.org\/10.1038\/s41583-018-0002-7.","journal-title":"Nat Rev Neurosci"},{"key":"2086_CR119","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3389\/fnagi.2017.00360","volume":"9","author":"X Guan","year":"2017","unstructured":"Guan X, Zeng Q, Guo T, et al. Disrupted Functional Connectivity of Basal Ganglia across Tremor-Dominant and Akinetic\/Rigid-Dominant Parkinson\u2019s Disease. Front Aging Neurosci. 2017;9:360. https:\/\/doi.org\/10.3389\/fnagi.2017.00360.","journal-title":"Front Aging Neurosci"},{"issue":"12","key":"2086_CR120","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00234-018-2101-6","volume":"60","author":"Y Hou","year":"2018","unstructured":"Hou Y, Ou R, Yang J, Song W, Gong Q, Shang H. Patterns of striatal and cerebellar functional connectivity in early-stage drug-naive patients with Parkinson\u2019s disease subtypes. Neuroradiology. 2018;60(12):1323\u201333. https:\/\/doi.org\/10.1007\/s00234-018-2101-6.","journal-title":"Neuroradiology"},{"key":"2086_CR121","doi-asserted-by":"publisher","unstructured":"Jiang LL, Zhang XL, Hu HY. Co-aggregation of TDP-43 with other pathogenic proteins and their co-pathologies in neurodegenerative diseases. Int J Mol Sci. 2024;25(22). https:\/\/doi.org\/10.3390\/ijms252212380.","DOI":"10.3390\/ijms252212380"},{"key":"2086_CR122","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1063-5823(10)66014-0","volume":"66","author":"I Bezprozvanny","year":"2010","unstructured":"Bezprozvanny I. Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders. Curr Top Membr. 2010;66:323\u201341. https:\/\/doi.org\/10.1016\/S1063-5823(10)66014-0.","journal-title":"Curr Top Membr"},{"issue":"3","key":"2086_CR123","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.gde.2009.02.009","volume":"19","author":"KM Carlson","year":"2009","unstructured":"Carlson KM, Andresen JM, Orr HT. Emerging pathogenic pathways in the spinocerebellar ataxias. Curr Opin Genet Dev. 2009;19(3):247\u201353. https:\/\/doi.org\/10.1016\/j.gde.2009.02.009","journal-title":"Curr Opin Genet Dev"},{"issue":"2","key":"2086_CR124","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12311-009-0144-2","volume":"9","author":"A Matilla-Duenas","year":"2010","unstructured":"Matilla-Duenas A, Sanchez I, Corral-Juan M, Davalos A, Alvarez R, Latorre P. Cellular and molecular pathways triggering neurodegeneration in the spinocerebellar ataxias. Cerebellum. 2010;9(2):148\u201366. https:\/\/doi.org\/10.1007\/s12311-009-0144-2.","journal-title":"Cerebellum"},{"issue":"6","key":"2086_CR125","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1212\/wnl.55.6.800","volume":"55","author":"K Gwinn-Hardy","year":"2000","unstructured":"Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology. 2000;55(6):800\u20135. https:\/\/doi.org\/10.1212\/wnl.55.6.800.","journal-title":"Neurology"},{"issue":"11","key":"2086_CR126","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1007\/s00415-019-09382-1","volume":"267","author":"C Raccagni","year":"2020","unstructured":"Raccagni C, Nonnekes J, Bloem BR, et al. Gait and postural disorders in parkinsonism: a clinical approach. J Neurol. 2020;267(11):3169\u201376. https:\/\/doi.org\/10.1007\/s00415-019-09382-1.","journal-title":"J Neurol"},{"issue":"Pt 4","key":"2086_CR127","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/brain\/122.4.769","volume":"122","author":"K Burk","year":"1999","unstructured":"Burk K, Globas C, Bosch S, et al. Cognitive deficits in spinocerebellar ataxia 2. Brain. 1999;122(Pt 4):769\u201377. https:\/\/doi.org\/10.1093\/brain\/122.4.769.","journal-title":"Brain"},{"issue":"3","key":"2086_CR128","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1017\/S1355617715000132","volume":"21","author":"I Vaca-Palomares","year":"2015","unstructured":"Vaca-Palomares I, Diaz R, Rodriguez-Labrada R, et al. Strategy use, planning, and rule acquisition deficits in spinocerebellar ataxia type 2 patients. J Int Neuropsychol Soc. 2015;21(3):214\u201320. https:\/\/doi.org\/10.1017\/S1355617715000132.","journal-title":"J Int Neuropsychol Soc"},{"issue":"2","key":"2086_CR129","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1212\/WNL.0000000000200349","volume":"99","author":"TX Chen","year":"2022","unstructured":"Chen TX, Lin CR, Aumann MA, et al. Impulsivity Trait Profiles in Patients With Cerebellar Ataxia and Parkinson Disease. Neurology. 2022;99(2):e176\u201386. https:\/\/doi.org\/10.1212\/WNL.0000000000200349.","journal-title":"Neurology"},{"issue":"3 Suppl 1","key":"2086_CR130","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1002\/ana.410440717","volume":"44","author":"EC Hirsch","year":"1998","unstructured":"Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson\u2019s disease: a role in neurodegeneration? Ann Neurol. 1998;44(3 Suppl 1):S115\u201320. https:\/\/doi.org\/10.1002\/ana.410440717.","journal-title":"Ann Neurol"},{"issue":"Pt 1","key":"2086_CR131","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/brain\/awh008","volume":"127","author":"RC Dale","year":"2004","unstructured":"Dale RC, Church AJ, Surtees RA, et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain. 2004;127(Pt 1):21\u201333. https:\/\/doi.org\/10.1093\/brain\/awh008.","journal-title":"Brain"},{"key":"2086_CR132","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.coi.2014.03.007","volume":"29","author":"G Pawelec","year":"2014","unstructured":"Pawelec G, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. Curr Opin Immunol. 2014;29:23\u20138. https:\/\/doi.org\/10.1016\/j.coi.2014.03.007.","journal-title":"Curr Opin Immunol"},{"key":"2086_CR133","doi-asserted-by":"crossref","unstructured":"Saavedra-L\u00f3pez E, Casanova PV, Cribaro GP, Barcia C. Chapter 38 - Neuroinflammation in movement disorders. In: Steiner H, Tseng KY (eds.) Handbook of Behavioral Neuroscience: Elsevier; 2016, pp 771\u2009\u2013\u200982.","DOI":"10.1016\/B978-0-12-802206-1.00038-6"},{"issue":"5","key":"2086_CR134","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/mds.29359","volume":"38","author":"Y Vazquez-Mojena","year":"2023","unstructured":"Vazquez-Mojena Y, Rodriguez-Cordova Y, Dominguez-Barrios Y, et al. Peripheral Inflammation Links with the Severity of Clinical Phenotype in Spinocerebellar Ataxia 2. Mov Disord. 2023;38(5):880\u20135. https:\/\/doi.org\/10.1002\/mds.29359.","journal-title":"Mov Disord"},{"issue":"10","key":"2086_CR135","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.2174\/011570159X379620250225075810","volume":"23","author":"C Tang","year":"2025","unstructured":"Tang C, Deng Q, Yuan X, et al. Peripheral Inflammation Profile of Cerebellar Ataxia. Curr Neuropharmacol. 2025;23(10):1276\u201386. https:\/\/doi.org\/10.2174\/011570159X379620250225075810.","journal-title":"Curr Neuropharmacol"},{"key":"2086_CR136","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuroscience.2015.01.003","volume":"289","author":"M Cvetanovic","year":"2015","unstructured":"Cvetanovic M, Ingram M, Orr H, Opal P. Early activation of microglia and astrocytes in mouse models of spinocerebellar ataxia type 1. Neuroscience. 2015;289:289\u201399. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.01.003.","journal-title":"Neuroscience"},{"key":"2086_CR137","doi-asserted-by":"publisher","unstructured":"Nam Y, Yoon D, Hong J, et al. Therapeutic effects of human mesenchymal stem cells in a mouse model of cerebellar ataxia with neuroinflammation. J Clin Med. 2020;9(11). https:\/\/doi.org\/10.3390\/jcm9113654.","DOI":"10.3390\/jcm9113654"}],"container-title":["The Cerebellum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-02086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-02086-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12311-026-02086-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:02:36Z","timestamp":1792792956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12311-026-02086-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":137,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2086"],"URL":"https:\/\/doi.org\/10.1007\/s12311-026-02086-z","relation":{},"ISSN":["1473-4230"],"issn-type":[{"value":"1473-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JM-20 is a patented compound developed through a collaborative effort involving the Centro de Investigaci\u00f3n y Desarrollo de Medicamentos (CIDEM) and Havana University (UH), which holds the intellectual property rights involved in its chemical design and development. Two authors (L.A.F.\u2010F and Y.N.\u2010F) are co-founders of the entity associated with the development of JM-20. These relationships represent potential competing interests and are disclosed for transparency. Importantly, the present review aims to provide a balanced assessment of the available evidence regarding JM-20 and does not constitute an endorsement of its therapeutic efficacy. Although JM-20 has shown promising preclinical properties and clinical studies are planned, its therapeutic efficacy, safety, and translational potential remain to be established through appropriately designed clinical investigations. To date, all available evidence supporting JM-20 is derived from preclinical studies. L.A.F.\u2010F and Y.N.\u2010F. are co\u2010inventors on patent EP2487174A2 and WO2017190713 related to JM\u201020 for the treatment of diseases of the central nervous and vascular systems.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not aplicable.","order":2,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"144"}}